Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Abstract
Muscarinic acetylcholine receptors (mAChRs), M(1)-M(5), regulate the activity of numerous fundamental central and peripheral functions. The lack of small-molecule ligands that can block or activate specific mAChR subtypes with high selectivity has remained a major obstacle in defining the roles of the individual receptor subtypes and in the development of novel muscarinic drugs. Recently, phenotypic analysis of mutant mouse strains deficient in each of the five mAChR subtypes has led to a wealth of new information regarding the physiological roles of the individual receptor subtypes. Importantly, these studies have identified specific mAChR-regulated pathways as potentially novel targets for the treatment of various important disorders including Alzheimer's disease, schizophrenia, pain, obesity and diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Gq/11-coupled M1, M3 and M5 mAChRs elicit Ca2+ release from the endoplasmic reticulum (ER) by activating the downstream phospholipase C/inositol 1,4,5-trisphosphate/inositol 1,4,5-trisphosphate receptor (PLC/IP3/IP3R) cascade49, the same pathway triggered by TCR signaling.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [49]
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
The role of acetylcholine in learning and memory
Hasselmo, M. E. (2006) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2006.09.002 · Cited by 1,693 · cited 1×
“Alzheimer's disease and cognitive impairments A convincing body of data indicate that mAChRs have central roles in facilitating cognitive function”
BackgroundInternational Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors
Caulfield, M. P., & Birdsall, N. J. M. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01362-0 · Cited by 1,474
Muscarinic Receptors—Characterization, coupling and function
Caulfield, M. P. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90027-b · Cited by 1,277
Wise, R. A. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80079-1 · Cited by 1,072
Koob, G. F., Sanna, P. P., & Bloom, F. E. (1998) · Neuron · doi:10.1016/s0896-6273(00)80557-7 · Cited by 1,026
The current status of the dopamine hypothesis of schizophrenia
CARLSSON, A. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90012-7 · Cited by 958
Autonomic regulation of islet hormone secretion - Implications for health and disease
Ahrén, B. (2000) · Diabetologia · doi:10.1007/s001250051322 · Cited by 909
Cited by
Items 101–200 of 671
FRET-based sensors for the human M1-, M3-, and M5-acetylcholine receptors
Ziegler, N., Bätz, J., Zabel, U., Lohse, M. J., & Hoffmann, C. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.07.060 · Cited by 79
A Photoswitchable Dualsteric Ligand Controlling Receptor Efficacy
Agnetta, L., Kauk, M., Cañizal, M. C. A., Messerer, R., Holzgrabe, U., Hoffmann, C., & Decker, M. W. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701524 · Cited by 79
Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs
Hollingsworth, S. A., Kelly, B., Valant, C., Michaelis, J. A., Mastromihalis, O., Thompson, G., Venkatakrishnan, A. J., Hertig, S., Scammells, P. J., Sexton, P. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11062-7 · Cited by 73
Allosteric modulators targeting CNS muscarinic receptors
Böck, A., Schrage, R., & Mohr, K. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.024 · Cited by 91
Impact of Altered Cholinergic Tones on the Neurovascular Coupling Response to Whisker Stimulation
Lecrux, C., Sandoe, C. H., Neupane, S., Kropf, P., Toussay, X., Tong, X.-K., Lacalle-Aurioles, M., Shmuel, A., & Hamel, E. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1784-16.2016 · Cited by 76
Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma
Zheng, C., Snow, B. E., Elia, A. J., Nechanitzky, R., Dominguez-Brauer, C., Liu, S., Tong, Y., Cox, M. A., Focaccia, E., Wakeham, A. C., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00624-w · Cited by 75
“The G q/11 -coupled M1, M3 and M5 mAChRs elicit Ca 2+ release from the endoplasmic reticulum (ER) by activating the downstream phospholipase C/inositol 1,4,5-trisphosphate/inositol 1,4,5-trisphosphate receptor (PLC/IP 3 /IP 3 R) cascade 49 , the same pathway triggered by TCR signaling.”
BackgroundGentry, P. R., Kokubo, M., Bridges, T. M., Kett, N. R., Harp, J. M., Cho, H. P., Smith, E. W., Chase, P. S., Hodder, P., Niswender, C. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4013246 · Cited by 77
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
Coyle, J. T., Balu, D., Benneyworth, M., Basu, A., & Roseman, A. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/jcoyle · Cited by 74
Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice
Schmidt, L. S., Thomsen, M., Weikop, P., Dencker, D., Wess, J., Woldbye, D. P. D., Wortwein, G., & Fink-Jensen, A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2225-4 · Cited by 74
Self-citationCholinergic Functioning in Stimulant Addiction: Implications for Medications Development
Sofuoglu, M., & Mooney, M. (2009) · CNS Drugs · doi:10.2165/11310920-000000000-00000 · Cited by 72
Martins-Silva, C., De Jaeger, X., Guzman, M. S., Lima, R. D. F., Santos, M. S., Kushmerick, C., Gomez, M. V., Caron, M. G., Prado, M. A. M., & Prado, V. F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017611 · Cited by 73
Clinical management of negative symptoms of schizophrenia: An update
Tsapakis, E.-M., Dimopoulou, T., & Tarazi, F. I. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.008 · Cited by 85
Long-acting muscarinic receptor antagonists for the treatment of respiratory disease
Cazzola, M., Page, C. P., & Matera, M. G. (2012) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2012.12.006 · Cited by 78
Bartko, S. J., Romberg, C., White, B., Wess, J., Bussey, T. J., & Saksida, L. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.023 · Cited by 87
Self-citationAllosteric modulation of kinases and GPCRs: design principles and structural diversity
Lewis, J. A., Lebois, E. P., & Lindsley, C. W. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.02.014 · Cited by 77
AGAP1/AP‐3‐dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release
Bendor, J., Lizardi-Ortiz, J. E., Westphalen, R. I., Brandstetter, M., Hemmings, H. C., Sulzer, D., Flajolet, M., & Greengard, P. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.154 · Cited by 77
Physiological and Pathophysiological Implications of Synaptic Tau
Regan, P., Whitcomb, D. J., & Cho, K. (2017) · The Neuroscientist · doi:10.1177/1073858416633439 · Cited by 71
Intracellular GPCRs Play Key Roles in Synaptic Plasticity
Jong, Y.-J. I., Harmon, S. K., & O’Malley, K. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00516 · Cited by 77
Pannell, M., Meier, M. A., Szulzewsky, F., Matyash, V., Endres, M., Kronenberg, G., Prinz, V., Waiczies, S., Wolf, S. A., & Kettenmann, H. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0962-y · Cited by 75
Antinociceptive activity of Mirabilis jalapa in mice
Walker, C. I. B., Trevisan, G., Rossato, M. F., Franciscato, C., Pereira, M. E., Ferreira, J., & Manfron, M. P. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.08.002 · Cited by 69
Akyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69
“Expressional and functional changes on mAChRs are associated with the pathogenesis of neurological diseases such as AD, and may be targets for intervention [200, 201].”
The antipsychotic potential of muscarinic allosteric modulation
Bridges, T. M., Lebois, E. P., Hopkins, C. R., Wood, M. R., Jones, C. K., Conn, P. J., & Lindsley, C. W. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.4.1416977 · Cited by 70
Gericke, A., Sniatecki, J. J., Mayer, V. G. A., Goloborodko, E., Patzak, A. R., Wess, J., & Pfeiffer, N. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00982.2010 · Cited by 68
Self-citationStructural insights into the subtype-selective antagonist binding to the M2 muscarinic receptor
Suno, R., Lee, S., Maeda, S., Yasuda, S., Yamashita, K., Hirata, K., Horita, S., Tawaramoto, M. S., Tsujimoto, H., Murata, T., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0152-y · Cited by 68
Bridges, T. M., Kennedy, J. P., Cho, H. P., Breininger, M. L., Gentry, P. R., Hopkins, C. R., Conn, P. J., & Lindsley, C. W. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.089 · Cited by 67
Muscarinic Receptors as Model Targets and Antitargets for Structure-Based Ligand Discovery
Kruse, A. C., Weiss, D. R., Rossi, M., Hu, J., Hu, K., Eitel, K., Gmeiner, P., Wess, J., Kobilka, B. K., & Shoichet, B. K. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.087551 · Cited by 73
Self-citationClassics in Chemical Neuroscience: Xanomeline
Bender, A. M., Jones, C. K., & Lindsley, C. W. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00001 · Cited by 71
Wang, Z., Liu, Q., Zhang, R., Liu, S., Xia, Z., & Hu, Y. G. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.07.041 · Cited by 70
Avlani, V. A., Langmead, C. J., Guida, E., Wood, M. D., Tehan, B. G., Herdon, H. J., Watson, J. M., Sexton, P. M., & Christopoulos, A. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064345 · Cited by 65
Uncovering patterns of atomic interactions in static and dynamic structures of proteinsPreprint
Venkatakrishnan, A., Fonseca, R., Ma, A. K., Hollingsworth, S. A., Chemparathy, A., Hilger, D., Kooistra, A. J., Ahmari, R., Babu, M. M., Kobilka, B. K., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/840694 · Cited by 72
Dencker, D., Thomsen, M., Wörtwein, G., Weikop, P., Cui, Y., Jeon, J., Wess, J., & Fink‐Jensen, A. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200110q · Cited by 72
Self-citationPark, K., Haberberger, R. V., Gordon, T. P., & Jackson, M. W. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30282 · Cited by 69
Genetics of ısolated growth hormone deficiency
Mullis, P. E. (2010) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.v2i2.52 · Cited by 73
Chasing the Full Free Energy Landscape of Neuroreceptor/Ligand Unbinding by Metadynamics Simulations
Capelli, R., Bochicchio, A. M., Piccini, G., Casasnovas, R., Carloni, P., & Parrinello, M. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b00118 · Cited by 67
Wright, M. C., Potluri, S., Wang, X., Dentcheva, E., Gautam, D., Tessler, A. R., Wess, J., Rich, M. M., & Son, Y. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.2276-09.2009 · Cited by 63
Self-citationMistry, S. N., Valant, C., Sexton, P. M., Capuano, B., Christopoulos, A., & Scammells, P. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400540b · Cited by 63
Jin, R. M., Xing, Z., Kong, D., Yan, X., Liu, F., Gao, Y. L., Sun, P., Liang, X., & Lu, G. (2019) · Journal of Materials Chemistry B · doi:10.1039/c8tb02987c · Cited by 63
Pharmacology, toxicology and clinical safety of glycopyrrolate
Chabicovsky, M., Winkler, S., Soeberdt, M., Kilić, A., Masur, C., & Abels, C. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.03.016 · Cited by 63
Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders
Digby, G. J., Shirey-Rice, J. K., & Conn, P. J. (2010) · Molecular BioSystems · doi:10.1039/c002938f · Cited by 69
Structural Basis of M3 Muscarinic Receptor Dimer/Oligomer Formation
McMillin, S. M., Heusel, M., Liu, T., Costanzi, S., & Wess, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.259788 · Cited by 66
Self-citationZeng, Q., Wang, S., Li, M., Wang, S., Guo, C., Ruan, X., Watanabe, R., Lai, Y., Huang, Y., 殷晓煜, et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.010 · Cited by 60
Wang, L., Zhi, X., Zhang, Q., Wei, S., Li, Z., Zhou, J., Jiang, J., Zhu, Y., Yang, L., Xu, H., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-4011-0 · Cited by 64
Veeraragavan, S., Bui, N., Perkins, J. R., Yuva‐Paylor, L. A., Carpenter, R. L., & Paylor, R. E. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2276-6 · Cited by 71
Alvarez‐Curto, E., Prihandoko, R., Tautermann, C. S., Zwier, J. M., Pediani, J. D., Lohse, M. J., Hoffmann, C., Tobin, A. B., & Milligan, G. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.074674 · Cited by 67
Barak, S., & Weiner, I. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001549 · Cited by 70
Alvarez‐Curto, E., Ward, R. J., Pediani, J. D., & Milligan, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.122184 · Cited by 63
Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?
Williams, M. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.171751 · Cited by 65
Osborne, P. G., Ko, Y., Wu, M., & Lee, C. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.06.039 · Cited by 58
The Conductor of the Autonomic Orchestra
Vinik, A. I. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00071 · Cited by 57
Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors
Barua, S., Kim, J. Y., Kim, J. Y., Kim, J. H., & Lee, J. E. (2019) · Neurochemical Research · doi:10.1007/s11064-018-02712-1 · Cited by 61
Kundu, S., Kumar, S., & Bajaj, A. (2015) · IUBMB Life · doi:10.1002/iub.1399 · Cited by 56
“Five muscarinic receptors (M1–M5) control many physiological processes through acetylcholine receptors and any malfunction would lead to both neurodegenerative and metabolic diseases (37).”
BackgroundDencker, D., Weikop, P., Sørensen, G., Woldbye, D. P. D., Wörtwein, G., Wess, J., & Fink‐Jensen, A. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2751-8 · Cited by 58
Self-citationde Azúa, I. R., Gautam, D., Guettier, J., & Wess, J. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.10.004 · Cited by 70
Self-citationCroy, C. H., Schober, D. A., Xiao, H., Quets, A. T., Christopoulos, A., & Felder, C. C. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.091751 · Cited by 56
Song, Z., Meyerson, B. A., & Linderoth, B. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.02.044 · Cited by 60
Dolan, B., Ermund, A., Martínez‐Abad, B., Johansson, M., & Hansson, G. C. (2022) · Science Signaling · doi:10.1126/scisignal.abl5848 · Cited by 57
Substâncias de origem vegetal potencialmente úteis na terapia da asma
Corrêa, M. F. P., Melo, G. O. D., & Costa, S. S. (2008) · Revista Brasileira de Farmacognosia · doi:10.1590/s0102-695x2008000500025 · Cited by 54
A Review of the Cholinergic System and Therapeutic Approaches to Treat Brain Disorders
Bertrand, D., & Wallace, T. L. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_141 · Cited by 73
Bridges, T. M., Kennedy, J. P., Noetzel, M. J., Breininger, M. L., Gentry, P. R., Conn, P. J., & Lindsley, C. W. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.109 · Cited by 55
Ragozzino, M. E., Artis, S., Singh, A. T., Twose, T. M., Beck, J. E., & Messer, W. S. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187625 · Cited by 53
Anti-nociceptive effect of stigmasterol in mouse models of acute and chronic pain
Walker, C. I. B., Oliveira, S. M., Tonello, R., Rossato, M. F., Brum, E. D. S., Ferreira, J., & Trevisan, G. (2017) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-017-1416-x · Cited by 58
Gautam, D., Jeon, J., Li, J. H., Han, S., Hamdan, F. F., Cui, Y., Lü, H., Deng, C., Gavrilova, O., & Wess, J. (2008) · Journal of Receptors and Signal Transduction · doi:10.1080/10799890801942002 · Cited by 59
Self-citationMatschinsky, F., Zelent, B., Doliba, N., Kaestner, K., Vanderkooi, J., Grimsby, J., Berthel, S., & Sarabu, R. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-17214-4_15 · Cited by 50
Differential Muscarinic Modulation in the Olfactory Bulb
Smith, R. S., Hu, R., DeSouza, A., Eberly, C. L., Krahe, K., Chan, W., & Araneda, R. C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0099-15.2015 · Cited by 51
Li, J. H., Gautam, D., Han, S.-J., Guettier, J.-M., Cui, Y., Lu, H., Deng, C., O'Hare, J., Jou, W., Gavrilova, O., et al. (2009) · Diabetes · doi:10.2337/db09-0522 · Cited by 51
Self-citationPhysiological roles of CNS muscarinic receptors gained from knockout mice
Thomsen, M., Sørensen, G., & Dencker, D. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.011 · Cited by 63
High capacity in G protein-coupled receptor signaling
Keshelava, A., Solis, G. P., Hersch, M., Koval, A., Kryuchkov, M., Bergmann, S., & Katanaev, V. L. (2018) · Nature Communications · doi:10.1038/s41467-018-02868-y · Cited by 56
Fink‐Jensen, A., Schmidt, L. S., Dencker, D., Schülein, C., Wess, J., Wörtwein, G., & Woldbye, D. P. D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.018 · Cited by 51
Self-citationMuscarinic Agonists for the Treatment of Cognition in Schizophrenia
Sellin, A. K., Shad, M. U., & Tamminga, C. A. (2008) · CNS Spectrums · doi:10.1017/s1092852900014048 · Cited by 50
Cholinergic Regulation of Airway Inflammation and Remodelling
Kolahian, S., & Gosens, R. (2012) · Journal of Allergy · doi:10.1155/2012/681258 · Cited by 55
Darby, M., Schnoeller, C., Vira, A., Culley, F. J., Bobat, S., Logan, E., Kirstein, F., Wess, J., Cunningham, A. F., Brombacher, F., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004636 · Cited by 58
Self-citationLyukmanova, E. N., Shenkarev, Z. O., Shulepko, M. A., Paramonov, A. S., Chugunov, A. O., Janíčková, H., Dolejší, E., Doležal, V., Utkin, Y. N., Tsetlin, V. I., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.656595 · Cited by 54
Agnetta, L., Bermúdez, M., Riefolo, F., Matera, C., Claro, E., Messerer, R., Littmann, T., Wolber, G., Holzgrabe, U., & Decker, M. W. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01822 · Cited by 58
Gericke, A., Sniatecki, J. J., Goloborodko, E., Steege, A., Zavaritskaya, O., Vetter, J. M., Grus, F. H., Patzak, A. R., Wess, J., & Pfeiffer, N. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7370 · Cited by 51
Self-citationSalah-Uddin, H., Scarr, E., Pavey, G., Harris, K., Hagan, J. J., Dean, B., Challiss, R. A. J., & Watson, J. M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.41 · Cited by 49
Role of the Central Cholinergic System in the Therapeutics of Schizophrenia
Terry, Jr. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777247 · Cited by 48
Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development
Kruse, A. C., Hu, J., Kobilka, B. K., & Wess, J. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.02.006 · Cited by 47
Self-citationLebois, E. P., Schroeder, J. P., Esparza, T. J., Bridges, T. M., Lindsley, C. W., Conn, P. J., Brody, D. L., Daniels, J. S., & Levey, A. I. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00278 · Cited by 49
Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols
Tveter, K. M., Mezhibovsky, E., Wu, Y., & Roopchand, D. E. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108457 · Cited by 53
Johnson, C. R., Kangas, B. D., Jutkiewicz, E. M., Bergman, J., & Coop, A. (2022) · Biomedicines · doi:10.3390/biomedicines10020398 · Cited by 53
Elucidating pathway-selective biased CCKBR agonism for Alzheimer’s disease treatment
Wang, J., Sha, X.-Y., Shao, Y., Zhang, Z.-H., Huang, S.-M., Lin, H., Gan, S., Zhang, N., Xia, X., Sun, Y.-N., et al. (2025) · Cell · doi:10.1016/j.cell.2025.10.034 · Cited by 56
Salovich, J. M., Vinson, P. N., Sheffler, D. J., Lamsal, A., Utley, T. J., Blobaum, A. L., Bridges, T. M., Le, U., Jones, C. K., Wood, M. R., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.109 · Cited by 45
Xu, J., Wang, Q., Hübner, H., Hu, Y., Niu, X., Wang, H., Maeda, S., Inoue, A., Tao, Y., Gmeiner, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35726-z · Cited by 47
Gautam, D., de Azua, I. R., Li, J. H., Guettier, J.-M., Heard, T., Cui, Y., Lu, H., Jou, W., Gavrilova, O., Zawalich, W. S., et al. (2010) · Endocrinology · doi:10.1210/en.2010-0519 · Cited by 44
Self-citationKim, B., Hawes, S., Gillani, F., Wallace, L. J., & Blackwell, K. T. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002953 · Cited by 48
Kennedy, J. P., Bridges, T. M., Gentry, P. R., Brogan, J. T., Kane, A. S., Jones, C. K., Brady, A. E., Shirey-Rice, J. K., Conn, P. J., & Lindsley, C. W. (2009) · ChemMedChem · doi:10.1002/cmdc.200900231 · Cited by 43
Ligand biological activity predicted by cleaning positive and negative chemical correlations
Lee, A. A., Yang, Q., Bassyouni, A., Butler, C. R., Hou, X., Jenkinson, S. G., & Price, D. A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810847116 · Cited by 44
Dominant Negative AT2 Receptor Oligomers Induce G-protein Arrest and Symptoms of Neurodegeneration
AbdAlla, S., Lother, H., el Missiry, A., Sergeev, P., Langer, A., el Faramawy, Y., & Quitterer, U. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m808277200 · Cited by 45
Aistrup, G. L., Villuendas, R., Ng, J., Gilchrist, A., Lynch, T. W., Gordon, D., Cokic, I., Mottl, S., Zhou, R., Dean, D. A., et al. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp148 · Cited by 42
Suno, R., Maeda, S., Yasuda, S., Yamashita, K., Hirata, K., Horita, S., Tawaramoto, M. S., Tsujimoto, H., Murata, T., Kinoshita, M., et al. (2017) · Worldwide Protein Data Bank · doi:10.2210/pdb5yc8/pdb · Cited by 42
Servent, D., Blanchet, G., Mourier, G., Marquer, C., Marcon, E., & Fruchart‐Gaillard, C. (2011) · Toxicon · doi:10.1016/j.toxicon.2011.08.004 · Cited by 41
Le, U., Melancon, B. J., Bridges, T. M., Vinson, P. N., Utley, T. J., Lamsal, A., Rodriguez, A. L., Venable, D. F., Sheffler, D. J., Jones, C. K., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.073 · Cited by 41
An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators
Kebig, A., Kostenis, E., Mohr, K., & Mohr‐Andrä, M. (2009) · Journal of Receptors and Signal Transduction · doi:10.1080/10799890903047437 · Cited by 41
Greig, N. H., Reale, M., & Tata, A. M. (2013) · Recent Patents on CNS Drug Discovery · doi:10.2174/1574889811308020003 · Cited by 51
Daval, S. B., Valant, C., Bonnet, D., Kellenberger, E., Hibert, M., Galzi, J., & Ilien, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201348t · Cited by 40
Dong, Y., Wang, Y., Wei, N., Zhang, Q., & Guan, Z. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1408-2 · Cited by 40
Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: A review
Coppola, M., & Mondola, R. (2011) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2011.605172 · Cited by 40
Zheng, G., Smith, A. M., Huang, X., Subramanian, K. L., Siripurapu, K. B., Deaciuc, A. G., Zhan, C., & Dwoskin, L. P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301774u · Cited by 42
Anisuzzaman, A. S. M., Uwada, J., Masuoka, T., Yoshiki, H., Nishio, M., Ikegaya, Y., Takahashi, N., Matsuki, N., Fujibayashi, Y., Yonekura, Y., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12306 · Cited by 41
Gautam, D., Jeon, J., Starost, M. F., Han, S.-J., Hamdan, F. F., Cui, Y., Parlow, A. F., Gavrilova, O., Szalayova, I., Mezey, E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900977106 · Cited by 38
Self-citation
Metadata
- Authors
- Wess, J., Eglen, R. M., & Gautam, D.
- Affiliations
- National Institutes of Health (US)
- PerkinElmer (United States) (US)
- Corresponding author
- Wess, Jürgen
- ORCID
- Wess, Jürgen
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-09
- Volume
- 6
- Issue
- 9
- Pages
- 721-733
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1999774383
- Cited by
- 637
- References
- 134
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 29 · 2023: 33 · 2022: 21 · 2021: 25 · 2020: 23 · 2019: 29 · 2018: 36 · 2017: 32 · 2016: 38 · 2015: 26 · 2014: 45 · 2013: 40 · 2012: 43
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- muscarinic receptors, knockout mice, Alzheimer's disease, schizophrenia, pain, obesity, diabetes mellitus, receptor function
- MeSH terms
- Animals, Disease Models, Animal, Ligands, Receptors, Muscarinic, Drug Design, Mice, Knockout, Muscarinic Agonists, Muscarinic Antagonists, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.